A fledgling biopharma company with heavy hedge fund backing is seemingly moving forward with its initial public offering, despite the stock market’s sharp selloff and overall volatility and growing concern that the Covid-19 virus is spreading throughout the United States.On Friday Renaissance Capital, an IPO